By Padmanabhan Ananthan March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin ...

Pfizer is hoping to challenge other biologics in the competitive AD market, which is currently dominated by blockbuster sellers, Dupixent and Rinvoq.

Pfizer Inc (NYSE:PFE) shares declined 1.15% to $26.74 in premarket trading Monday, even after the pharmaceutical company ...

Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. | Pfizer is ramping up plans for ...

Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...

Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma ...

Merck & Co.'s Keytruda in combination with an antibody-drug conjugate from Pfizer and Astellas Pharma led to a 47% reduction in the risk of tumor recurrence, progression or death in patients with ...

Pfizer announced Wednesday it has begun phases 2 and 3 of its pediatric clinical trial for Paxlovid, its COVID-19 antiviral treatment. The study will look into how effective and safe the treatment is ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...